RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats.
Bombesin and its mammalian equivalent, gastrin-releasing peptide (GRP), stimulate cell proliferation and are involved in the pathogenesis of several types of human cancer. Bombesin-like peptides also display neuroendocrine activities and regulate neural function. In the present study, we evaluated the effects of the bombesin/GRP receptor antagonist (D-Tpi(6), Leu(13) psi[CH(2)NH]-Leu(14)) bombesin-(6-14) (RC-3095), experimental antitumor drug, on memory in rats. Adult female Wistar rats were treated with an intraperitoneal injection of RC-3095 (0.2, 1.0 or 5.0 mg/kg) 30 min before training in either inhibitory avoidance or novel object recognition tasks. Retention test trials were carried out 1.5 (short-term memory) or 24 h (long-term memory) after training. RC-3095 at the doses of 0.2 or 1.0 mg/kg, but not at the dose of 5.0 mg/kg, impaired both short- and long-term inhibitory avoidance retention, but did not affect recognition memory. The memory-impairing effect of RC-3095 could not be attributed to alterations in sensorimotor functions. The results show that the antitumor drug/GRP antagonist RC-3095 impairs formation of aversive memory.
Roesler
Rafael
R
Preclinical Neuropharmacology Laboratory, Department of Pharmacology, Institute for Basic Health Sciences, and Center for Biotechnology, Federal University of Rio Grande do Sul, Pôrto Alegre, RS, Brazil. rroesler@terra.com.br
Kopschina
Márcia I
MI
Rosa
Renato M
RM
Henriques
João Antônio Pêgas
JA
Souza
Diogo Onofre
DO
Schwartsmann
Gilberto
G
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects* / Q000502:physiology; D001839:Bombesin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D005260:Female; D008569:Memory Disorders / Q000139:chemically induced; D010446:Peptide Fragments / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors* / Q000502:physiology; D021641:Recognition, Psychology / Q000187:drug effects* / Q000502:physiology
D010446:Peptide Fragments; D018004:Receptors, Bombesin; C071363:bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-; D001839:Bombesin